Onto Innovation stock price target raised by Oppenheimer to $180

Investing.comTuesday, October 14, 2025 at 1:04:37 PM
Oppenheimer has raised its price target for Onto Innovation's stock to $180, reflecting confidence in the company's growth potential. This adjustment is significant as it indicates a positive outlook for investors and suggests that Onto Innovation is well-positioned in the market, which could attract more interest from potential buyers.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Oppenheimer downgrades Astria Therapeutics stock rating to Perform on BioCryst acquisition
NegativeFinancial Markets
Oppenheimer has downgraded its stock rating for Astria Therapeutics to 'Perform' following the company's acquisition of BioCryst. This decision reflects concerns about the potential impact of the acquisition on Astria's future performance. Investors should pay attention to how this change might affect the company's growth trajectory and market position.
Flutter Entertainment stock price target lowered to $330 by Oppenheimer
NegativeFinancial Markets
Oppenheimer has lowered its stock price target for Flutter Entertainment to $330, reflecting concerns about the company's future performance. This adjustment is significant as it may influence investor confidence and market perception, potentially impacting Flutter's stock value in the coming months.
Broadcom stock rises on Oppenheimer’s reiterated Outperform rating
PositiveFinancial Markets
Broadcom's stock has seen a notable increase following Oppenheimer's reaffirmation of an Outperform rating. This positive outlook from a respected financial institution highlights investor confidence in Broadcom's future performance, suggesting that the company is well-positioned for growth in the tech sector. Such endorsements can significantly influence market trends and investor decisions, making this news particularly relevant for those tracking stock movements.
Onto Innovation stock price target raised to $120 from $110 at Stifel
PositiveFinancial Markets
Onto Innovation has received a boost as Stifel raises its stock price target from $110 to $120. This adjustment reflects growing confidence in the company's performance and potential for future growth, which is encouraging news for investors and could lead to increased interest in the stock.
Latest from Financial Markets
Grindr’s Billionaire Shareholder Explores Taking Dating App Private In $3 Billion Deal
PositiveFinancial Markets
Billionaire George Raymond Zage III is considering taking Grindr private in a potential $3 billion deal, with $1 billion in financing already secured. This move could reshape the dating app landscape and enhance Grindr's growth potential, making it an exciting development for users and investors alike.
BHP’s Slattery says Australia must cut red tape, power costs, to compete
PositiveFinancial Markets
BHP's Slattery emphasizes the need for Australia to reduce red tape and power costs to enhance its competitiveness in the global market. This is crucial as it could lead to increased investment and job creation, ultimately benefiting the economy and improving the standard of living for Australians.
Why Obamacare Is Keeping The Government On Shutdown
NeutralFinancial Markets
The ongoing debate over Obamacare is impacting the government's potential shutdown, as Democrats push for increased taxpayer funding for health care subsidies while Republicans resist these demands. This standoff highlights the need for both parties to engage in sensible reforms to address the healthcare system's challenges, which could ultimately benefit millions of Americans relying on these services.
EyePoint Pharmaceuticals prices $150 million public offering
PositiveFinancial Markets
EyePoint Pharmaceuticals has successfully priced a $150 million public offering, a significant move that reflects investor confidence in the company's future. This funding will likely support their ongoing research and development efforts, potentially leading to new treatments in the ophthalmology sector. Such financial backing is crucial for biotech firms as it enables them to innovate and expand their product pipelines, ultimately benefiting patients and shareholders alike.
Indian Equities Could Ride Asian Markets Rally on Fed Rate Cut Hopes
PositiveFinancial Markets
Indian equities are poised to benefit from a potential rally in Asian markets, fueled by hopes of a Federal Reserve rate cut. This news is significant as it suggests a favorable environment for investors, potentially leading to increased market activity and confidence in the Indian economy.
KKR, PAG Near Deal for Sapporo Real Estate for Over $2.6 Billion
PositiveFinancial Markets
KKR and PAG are making headlines with their joint bid to acquire Sapporo Holdings' real estate assets for over $2.6 billion. This deal is significant as it highlights the growing interest in real estate investments, especially in the beverage sector, and could reshape the landscape for Sapporo Holdings, allowing them to focus more on their core business.